Glycosylation as a strategy to improve antibody-based therapeutics.
about
Allergenicity of carbohydrates and their role in anaphylactic events.Therapeutic antibodies, vaccines and antibodyomesAdvances in recombinant antibody manufacturingGlycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical reviewFc glycans of therapeutic antibodies as critical quality attributesThe perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejectionTargeting the Fc receptor in autoimmune diseaseRecent advances in mammalian protein productionGlycotherapy: new advances inspire a reemergence of glycans in medicineMonoclonal antibody-based therapies for microbial diseasesDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityChemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan BiosynthesisStructural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycansSelective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor InteractionsEngineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal AntibodiesUnraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic ProteinsImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesFc gamma receptors: glycobiology and therapeutic prospectsAdvances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-lifeRapid high yield production of different glycoforms of Ebola virus monoclonal antibodyComparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc GlycoformsOptimal Synthetic Glycosylation of a Therapeutic AntibodyOptimal Synthetic Glycosylation of a Therapeutic AntibodyEnhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.Carbohydrates as allergens.Influence of glycosylation pattern on the molecular properties of monoclonal antibodies.Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationPost-translational modifications differentially affect IgG1 conformation and receptor binding.Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines.Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant.High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodiesHigh-throughput profiling of N-linked oligosaccharides in therapeutic antibodies using a microfluidic CD platform and MALDI-MS.A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancyCore fucosylation and IgG function in NAIT.Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.Glycosylation of therapeutic proteins: an effective strategy to optimize efficacyHigh throughput quantification of N-glycans using one-pot sialic acid modification and matrix assisted laser desorption ionization time-of-flight mass spectrometryLectin-carbohydrate interactions on nanoporous gold monoliths.
P2860
Q24599525-2EB142A1-7583-4DCB-A4D8-C9F9B8C8970CQ24599662-F92E2666-0C18-46DB-A4CB-3329A8CCC0A4Q26764949-0789D7CE-D289-467F-9C07-FC4C5A9FB71BQ26782025-5FE5E5FA-E34B-43EC-8DE6-8CBD1AD64BD6Q26799266-087D3D86-A315-4545-8EE8-479951AECBEAQ26862195-7ACDF695-598A-4B38-8DB6-5651574B04C6Q27002843-FAE475A6-C1D2-4A81-928F-889134BE2F3CQ27008285-888DA7DB-497C-459E-8662-4AF3E1935DA5Q27027997-BE30750D-2766-4BDF-954D-14A711AA8395Q27490830-DCA84A48-0A1F-44D9-8EC4-D4B60F99ABE9Q27654848-A0F2E1C7-6089-42B2-A6D0-487E1D28CDB9Q27673777-19B37D4A-4118-464E-9ADE-A334B4B94FE8Q27675205-8A0D9E2F-5A52-4EBB-899E-891F5490A92FQ27678384-1E813DC1-0423-4E62-8D7A-938536350D31Q27678524-309BCA98-BE5A-481B-98FF-EAFAE7C6713BQ28066498-0BCD0BE5-A5D2-4CAF-9A21-694C34AF78FDQ28069362-6252A757-B2C9-441C-B205-192372403764Q28076303-66746A1C-53AA-4602-B0CB-6944D9F3767AQ28079016-2A713008-3A69-4880-A743-67BB6F8DDC9BQ28743509-18E45855-8BB9-492E-A06C-3C3F6952F224Q28820826-4FD041F8-8581-4F3C-AE3A-F8536BFE44D0Q28831266-91870A19-0329-41E4-90D4-569D6719B6F3Q28831364-C0A6625C-D714-4979-8123-14760FDB5B88Q30224854-BBAAFFD8-4776-4EEC-B883-7C6EAD3253C5Q30301262-46C399F7-34A4-421A-AE0F-AAFA4C002FA4Q30360566-CAD1649C-4ED8-4C89-A69E-2E839FF052F9Q30360964-200F11DB-8841-48D0-8238-222BF6B49A6DQ30384877-5E1FC351-F2B1-427C-8149-45970E88B856Q30428210-5E422B22-BCD0-4918-B445-FC88AEC94B51Q30434648-BF624AD6-E302-40A7-AB53-6F87513854C1Q30675226-2E8622FD-9715-4CD4-A70D-23BE36010512Q30818421-F21695A0-E1D6-41C0-87EB-E76418B83140Q30993361-C33D6399-FB64-4E4F-9961-F293888BDE3CQ33411528-EEE4E444-F6F1-4D94-81E8-2854B49CFBB5Q33412852-9F71A358-CA81-45C1-814D-0A55FA0CD1F6Q33420853-820A87CD-3A94-4045-8268-6967B7678909Q33551688-5C6975BE-65A2-4BCA-88A0-7CF99A53B2FBQ33586660-78D5FC97-C8C9-49C7-886C-2B49DB0C6E24Q33619621-B942C4B4-DDF6-437A-AD76-E5BC6866B520Q33686539-19EB7F31-5F05-42C3-9F66-D80E1F904C26
P2860
Glycosylation as a strategy to improve antibody-based therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
gotara zanistî
@ku-latn
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
Glycosylation as a strategy to improve antibody-based therapeutics.
@en
Glycosylation as a strategy to improve antibody-based therapeutics.
@nl
type
label
Glycosylation as a strategy to improve antibody-based therapeutics.
@en
Glycosylation as a strategy to improve antibody-based therapeutics.
@nl
prefLabel
Glycosylation as a strategy to improve antibody-based therapeutics.
@en
Glycosylation as a strategy to improve antibody-based therapeutics.
@nl
P356
P1476
Glycosylation as a strategy to improve antibody-based therapeutics.
@en
P2093
Roy Jefferis
P2888
P304
P356
10.1038/NRD2804
P577
2009-03-01T00:00:00Z
P6179
1011803907